CubaHeal Research Department:

Professor Ricardo A. Gonzales MD Ph.D. DSc founded back in 1976 Cuba’s first health facility for substance abuse treatment at the Eduardo B. Ordaz Psychiatric Hospital in Havana. During his carrier of 40 years, he founded 17 similar facilities throughout Cuba making the hospital in Havana a national reference center for substance abuse treatment.  The Cuban approach to drug abuse is open for international patients as well. The legendary soccer player, Diego Maradona is certainly, the most well-known patient of Cuban program.

 

What’s a Cuban approach?

The program lasts for 97 days (14 weeks) and during that time, the patient goes through the process of detoxification and rehabilitation. All the details are worked out- the therapy is carried out in a natural environment, overseen by a team of highly trained professionals (multidisciplinary approach to the treatment is must!). Upon the conclusion, the re-evaluation and follow up visit are scheduled.

The facilities that accommodate patients are secured and reserved only for patients on a drug abuse treatment. The treatment principle applied relies on “therapeutic communities” where patients get a chance to talk and encourage each other, share their hopes, dreams, and frustrations, which altogether contributes to the recovery.

During the first week, the team of specialists decides if the patient should stay in the program or not. In case of excessive aggression, if the patient changes his mind (patients are admitted under their own free will) or because of other medical or non-medical reasons, the team releases the patient with a recommendation about further treatment. The patients who get admitted (a vast majority of them), undergo a series of lab tests, X-ray, ECG, and other necessary medical examination procedures. After the initial assessment, a personalized therapeutic plan is made.

During the three months period, the patient is undergoing individualized physical and psychological rehabilitation program to achieve behavioral changes that will allow him a healthy (long-term sustainable) rehabilitation. Specifically, the patient learns about how to control withdrawal symptoms, how to cope with cravings, new healthy lifestyle, how to eliminate harmful behaviors and accept responsibilities and develop his or her intellectual and labor potential to its maximum.

Multidisciplinary approach

The problem of drug abuse is complex and requires a team of many specialists- experienced internal medicine specialists, neurologists, psychologists, psychiatrists, nurses- all to be trained specifically for the treatment of drug abuse.

Drug abuse in some cases leads to a vicious, never-ending cycle of psychiatric problems- the drug abuse damages the brain which leads to psychiatric conditions (paranoid psychosis or schizophrenia for example), which deepens the problem of drug abuse and makes it even harder to quit. The art of treatment is to recognize and put under control the “layers of the problem” that developed into autonomous psychiatric conditions over time and target the treatment specifically towards addiction (once the problem of addiction is solved, other aspects of patient’s psychological condition are resolved much easier).

A number of neurological conditions due to brain damage develops in abusers over time. Recognizing and putting those under control is also very important.

To put it in simple words- drug abuse treatment is like a walk through the minefield. To get on the other side of it you need a trained and experienced team behind, otherwise, it’s just a guessing game (with low chances for success).

What happens after the patient has been admitted to the program?

After admission, each patient gets introduced with the program (the first week, personalized treatment, methods, goals, and other relevant info). After introduction procedure, the patient signs a therapeutic contract. Also, the patient writes his or her personal history, with self-assessment- this document helps the team of specialists to design a treatment plan and later on, after the rehabilitation is over, will help the patient understand the extent of treatment intervention he went through.

Most often, on the day of admission, the patient is introduced to the community and attends all activities with others. In case of severe withdrawal symptoms, the patient may be under intense medical attention until his or her condition stabilizes. After stabilization, the patient is integrated into the community.

Long-term goals of rehabilitation

The goal is lifelong abstinence from drugs and rehabilitation of consciousness, personality, and behavior. The program helps the patient make lifestyle changes that will incur the risk of relapse- patients are encouraged to avoid places, activities, and people that are cues to drug use, to identify, understand and resolve inside conflicts that may be misinterpreted as cravings (or have lead to drug abuse earlier).

Drug addictiveness is a complex problem that affects not only one’s health, but his or her social relations, family, and all other aspects of everyday life. The Cuban program is optimized to cope with all of these aspects and prepare a patient for a new drug-free life.

 

Besides drugs, the Cuban program deals with other addictions as well

Drug abuse is just one of the problems when it comes to addictive behaviors and substance abuse. Alcohol, tobacco use, marijuana and opiates abuse are also problems the Cuban program successfully deals with. Of course, the approach is optimized for each of these programs.

Readers take away

The Cuban substance abuse treatment programs are developing since 1976. Professor Ricardo A. Gonzales, founding the father of substance abuse treatment on Cuba and internationally recognized expert is active even today as a consultant, but what’s even more important is his legacy to Cuba- a National Reference Center for Substance Abuse in Havana and 17 more facilities throughout Cuba that deal with the issue. Besides Cubans, these programs are available to international clients as well.

The rehabilitation process takes 3 months (sometimes more), and a rough price of the entire process with all expenses included is $26.000 (the price may differ at the point you read this article, for more info, contact the National Reference Center for Substance Abuse in Havana. During those three months, the patient is under constant attention of a team of experts.


13023_2006_Article_40_Fig1_HTML.jpg

Current Challenges in the Treatment of Retinitis Pigmentosa

Retinitis pigmentosa (RP) represents a rare and severely debilitating group of disorders affecting vision that have a genetic background and are slowly progressive by nature (1).  Despite the continuing efforts of the scientific community directed towards the understanding and treatment of the disease, RP still remains incurable.  Management of RP was investigated in various preclinical models, as well as in numerous clinical trials on humans in the United States, however, the effective and safe solution to this problem was not yet found.

Retinitis pigmentosa causes a progressive and irreversible vision damage caused by deterioration of photosensitive cells (especially rods) in the retina (2).  Early symptoms usually represent the loss of the peripheral visual field, followed by further vision narrowing, which may eventually result in complete blindness.  Treatment options in the United States are currently quite limited.  The management of RP mostly includes vitamin supplementation, aiming to hold off the progression of the degenerative process.  However, even vitamin supplementation, besides its’ limited effectiveness, has its safety concerns.  Vitamin A supplementation is not recommended in certain individuals since it may cause fertility issues and severe osteoporosis (3).  Preventative measures, such as avoiding light exposure in the early phases of the disease did not prove to be highly effective.

When reviewing the current treatment options, it seems that RP still represents a challenging task.  In order to improve the quality of life of patients suffering from this degenerative and progressive disorder, Cuban experts have developed a sophisticated and effective method for the management of RP.

Suggested post: Cuban approach to cancer treatment

Solutions Offered by Cuban Experts

The main treatment objective is to limit the disease progression by improving the vascularization of the retina. The management of RP in Cubapracticed now, that is focused on eye vascularization, has been developed and improved for more than two decades.  The milestone of therapy is to bring as much blood, oxygen, and nutrients as possible to the eye.  This is being performed by encouraging the development of blood vessels.

There have been some attempts in Russia to transplant the stem cells that would develop into the healthy retinal tissue, however, scientists were mostly frustrated by failure since the stem cells could not successfully engraft due to the lack of the healthy vascular supply (4).  Cells remodeling was also attempted; however, this study was suspended due to the lack of efficacy.  Cuba offers a sustainable treatment option that focuses on limiting or completely inhibiting the progression of degenerative vascular changes in the retina. There are several treatment approaches that are being applied to the overall management plan.  They include eye surgery, ozone therapy, electrostimulation and drugs (5).

Micro-surgery

A very sophisticated and unique surgical technique is used to increase the blood flow within the part of the eye responsible for providing blood supply to the retina.  When this technique is performed, retina remains adequately nourished and oxygenated.  This allows normal retinal function and prevents further deterioration of vision.  By stimulating the blood flow within the retina, visual acuity increases, and retina is encouraged to grow, and not deteriorate.  The final result is stabilization of the disease and rapid improvement in both central and peripheral vision (6).  Ophthalmologists from all over the world refer their patients to Cuba, for this surgery to be performed due to its’ efficacy and safety.

Ozonotherapy

It has been recognized that ozone improves cell metabolism, boosts the cell energy levels and exhibits antioxidant properties (7).  The ozone is either administered rectally or being injected into the bloodstream. Ozone provides detoxification effects by blocking the harmful lipid peroxidation that occurs in retinal cells affected with retinitis pigmentosa.  The ozonotherapy also promotes the blood flow surrounding retina, thereby directly improving the retinal function.  In order to ensure the best possible results, the patient should receive 14 cycles of treatment during the course of the whole therapy.

Electro-stimulation

Electrical stimulation produces a micro-massage effect that stimulates micro-circulation and lymphatic drainage.  These effects promote electro-ionic balance and provide an additive effect to the ozonotherapy (8).  This method has demonstrated a high efficacy.  Another benefit of this treatment modality includes reinforcing the process of the perception of visual stimuli within the brain.  The electro-stimulation includes the application of pleasant therapeutic electrical currents on the head, neck, soles of the feet, and palms of the hands.  For the complete and best possible effect, 10-15 treatment sessions are needed to be performed.  During the full treatment course, drugs including immune-modulators, oxide-reductive substances, minerals, and vitamins are administered to boost the treatment effects.

Clinical Trials

Cuban scientists investigated the effects of ozone treatment on the visual field in participants that had retinitis pigmentosa.  This was a controlled, randomized and double-blind study, with the study design that ensures a high level of evidence.  68 participants were enrolled in the trial.  Half of the subjects received ozone treatment, while the other half received placebo.  The study demonstrated that three times more subjects in the ozone group experienced a significant improvement in the visual field, compared to those who received placebo. Subjects with early stages of the disease experienced greater improvement with more long-lasting effects, which underlines the importance of early intervention. Subjects at early phases of the disease also experienced more stable and sustainable treatment effects. In conclusion, this study showed that ozone treatment had beneficial effects on patients with RP.

Also read; Cuban Substance Abuse Treatment Program

Another double-blind, placebo-controlled study also evaluated the effects of ozone treatment in patients with retinitis pigmentosa.  This study had an even greater number of participants (168).  This study also demonstrated the significant improvement in patients treated with ozone therapy compared to patients that received placebo. Interestingly, approximately a half of the patients that had treatment response also succeeded to maintain the response for the longer period of time (9).

Checkout the latest novel medications developed in Cuba

A study that investigated the redox-balance in patients with RP receiving ozone treatment concluded that ozone therapy represents a safe therapeutic modality since no side effects related to treatment were observed during the course of the trial.  Therefore, ozone therapy can be safely administered to patients with RP without any risk of side effects (10).

Also read; Cuban Approach to Cancer Treatment

Conclusion

Treatment of RP still represents a challenging task in the western countries.  Vitamin supplements and avoiding excessive light are just not sufficient enough to provide any benefit to patients suffering from this severely debilitating illness.  Various treatment approaches including stem cells transplantation and remodeling of the retinal cells have failed to demonstrate effectiveness.  Stem cells failed to engraft, and retinal cell remodeling was not possible both because of the vascularization impairment that occurs in this serious illness.  Cuban researchers and medical experts decided to target exactly this disease characteristic by improving the blood flow in the eye, which allows retina to properly function.  Improvement of eye circulation ensures the adequate oxygenation of retinal tissue and postpones or completely stops the degenerative processes within the retina. Clinical trials and plenty of satisfied patients worldwide guarantee treatment success.  Thousands of international patients referred to Cuba for the treatment of RP have experienced benefits following treatment. Clinics in Cuba still represent the only hope for people suffering from this genetic disorder.  Cuban experts have found a solution to postpone or completely stop the development of the negative effects on the quality of life of patients suffering from RP.

Checkout this Woman in remission after receiving treatment in Cuba

REFERENCES:

  1. Baumgartner, W. (2000). Etiology, pathogenesis, and experimental treatment of retinitis pigmentosa. Medical Hypotheses, 54(5), 814-824.
  2. Medline Plus Encyclopedia. Retrieved on July 1st, 2018, from http://www.nlm.nih.gov/medlineplus/ency/article/001029.htm
  3. Jayashree N Sahni et al. (2011). Therapeutic Challenges to Retinitis Pigmentosa: From Neuroprotection to Gene Therapy. Curr Genomics. 12(4): 276–284.
  4. Health Services International (Servimed) Inc. Retrieved on July 1st 2018, from http://www.healthservicecuba.com/retinitis-pigmentosa/
  5. Centro Internacional de Retinosis Pigmentaria Camilio Cienfuegos de Cuba. Tratamiento cubano para la Retinosis Pigmentaria. Retrieved on July 1st, 2018, from http://www.infomed.sld.cu/instituciones/retinosis/quienesomos/quienesomos.html
  6. Garcia Layana, A. (2003). La cirugía de la retinosis pigmentaria en Cuba. Communication presented at Archivos de la Sociedad Española de Oftalmología, Madrid.
  7. Copello, M., Eguía, F., Menéndez, S., & Menéndez, N. (2003). Ozone Therapy in Patients with Retinitis Pigmentosa. Ozone: Science & Engineering, 25(3), 223-232.
  8. Berson, E., Remulla, J., Rosner, B., Sandberg, M., & Weigel-DiFranco, C. (1996). Evaluation of patients with retinitis pigmentosa receiving electric stimulation, ozonated blood, and ocular surgery in Cuba. Arch Ophthalmol, 114(5), 560-563.
  9. Pérez, L. J. (2004). Ozone therapy in retinitis pigmentosa. Communication presented at 4th International Symposia on Ozone Applications, Cuba.
  10. Menéndez, S., Hernández, F., & Copello, M. (2004). Ozone therapy and redox balance in patients with Retinitis Pigmentosa. Communication presented at 4th International Symposia on Ozone Applications.

autism-spectrum-disorder-managing-behaviour-1200x675.jpg

It has been estimated according to the data published by the World Health Organization that 1 in 160 children worldwide suffers from autism.  The exact number is quite challenging to estimate for various reasons.  It is presumed that Cuba has a lower rate of children with autism spectrum disorder when compared with the United States.  Yet, Cuba has taken autism quite seriously and constantly develops and improves strategies aimed to increase the quality of life of children with this serious medical disorder and their families.  The country has established specialized centers focused both on the treatment of children and inclusion of the families in the society, which is of course absolutely costs free.

In 2013, Cuba was the country to host the First International Forum on Autism and Inclusion.  This conference gathered the globally recognized experts in the field of autism spectrum disorder (ASD).  The focus of the conference was to establish methods and discuss the significance of an early diagnosis of ASD and effective inclusion of such families in the society.  The conference alone mirrors the country’s efforts to seek for the best possible ways to make the lives better for children with ASD and their families.

Treatment of Autism in Cuba

The program aimed to increase the quality of life of persons living with ASD is coordinated by the Cuban Ministry of Public Health and Ministry of Education.  Other public sectors including culture, media, and sports institutions are also involved in the program for helping ASD individuals to reach the best of their abilities.  The program consists of individualized, multi-disciplinary training aimed at developing and empowering skills.  The ASD individuals also receive specialized education and advocacy support.  The individualized treatment is tailored by the specialized Diagnostic Commission when the type and severity of the disease are taken into consideration.  Treatment is focused on early intervention.

The treatment for ASD is conducted in the peaceful and comfortable environment in order to ensure the best possible effects of the treatment plan and to allow the improvement the patient’s mental and physical abilities.  The objective of each individualized treatment plan is to ameliorate the symptoms of the disease and improve the child’s learning capacity.  As already mentioned, the treatment is tailored according to the individual needs of each child.

Accommodation

Each medical facility that deals will the treatment of autism is equipped with rooms that resemble those in a hotel (cable TV, phone, dry cleaning services).  The facility contains sauna, pool, gym, internet access, shops, and pharmacies.

Treatment Stage 1: Assessment

The first stage of treatment consists of detailed assessments and evaluations that include laboratory and imaging analyses, and consultations with different specialists.  The child is examined and evaluated by a pediatrician, neurologist, psychologist, speech therapist, and psychiatrist.  The laboratory panel consists of hemogram, serology testing, serum glucose, sedimentation, urine analyses, creatinine and liver functions tests.  Additionally, specific testing consists of magnetic resonance brain imaging, evoked potentials, and electroencephalography.  Each patient undergoes logopedic assessment, neuropsychological evaluation, Brunet-Lezine scale evaluation as well as psychotherapeutic treatment assessment.  Within the first stage, parents are also introduced to the team of experts and the treatment plan is referred to the parents once completed.  The phase duration is approximately one week, depending on the patient’s characteristics.

Treatment Stage 2: Therapy and Rehabilitation

The duration of actual treatment is approximately 30 days, but this may vary depending on the patient’s characteristics.  The tools that are used in the treatment of autism include equine therapy, occupational treatment, language therapy, sensorial stimulation, ozone treatment and trans-cranial electric stimulation if needed (in hyperkinetic patients).  Language treatment is carried out each day.  In the beginning, the language rehabilitation sessions last one hour during the day, but this is extended later to two sessions each day. 

Language rehabilitation usually lasts 20 days.  During this treatment, the child is being constables evaluated by the experts and the progress is being monitored.  Based on the effects of treatment, the language rehabilitation process is further re-tailored based on the response of each child.  Therefore, each treatment protocol is being adjusted by the characteristics of each child.  Language rehabilitation is broad and intensive.  During each treatment, specialist conducts sensorial stimulation techniques such as facial massage.  Specialized teams also work with family members or companions in order to ensure the best possible communication results.  Family members or companions are taught to conduct language exercises and sensorial stimulation as continuing the language training after the child leaves the facility is essential for obtaining good treatment results.

Occupational treatment is also a very important feature of the overall rehabilitation program.  This treatment aims to help the patients overcome the obstacles of physical and mental barriers present within the ASD, which restrict the everyday activities such as self-care, productivity, and participation in leisure activities.  The treatment is conducted each day in two sessions.  Specialists work with object identification, images projection and touching through interactive and didactic games.

As a part of occupational treatment, the children are engaged in outdoor activities.  Engaging and stimulative games and exercises are being tailored for each child in order to learn about the surroundings.  This treatment is also tailored based on the child’s preferences.  Children are stimulated with colors, various physical activities including swimming in the pool, soccer, horseback riding etc.  The specialists carefully monitor the children and adjust the program based on the child’s response to each stimulation.  The length and duration of occupational therapy are also assessed based on the child’s characteristics and the progress being made with this treatment approach.  This treatment has a goal to improve the patient’s productivity, physical performance, and sensorial activity.

Final Report and Recommendations

Once the treatment is considered completed, the experts will tailor the final report consisted of the diagnosis, severity, and prognosis of the ASD.  Based on the vigilant monitoring of the child during each stage of treatment, the experts will issue the comprehensive recommendations for each child regarding further treatments and ASD management approaches.

Readers Takeaway

Cuba is investing a lot of effort in advancing the management of children suffering from ASD.  Prestigious medical centers in Cuba have programs based on the extensive international experience in autism management.  Treatment protocols for ASD are in line with the globally accepted international medical standards.  Cuba invests in the training of staff that deals with kids suffering from ASD.  There is still a lot to be learned about ASD in order to provide the best possible treatments for ASD patient and their families.  Cuba has proven to take this issue seriously and professionally.



Life expectancy of Cuban population has increased significantly over the past decade.  In 2014, an average life expectancy was shown to be 78.5 years (1).  It is predicted that approximately a third of the entire population in Cuba is going to reach the age of 60 by the year 2030 (2).  The increased life expectancy, increase in the prevalence of elderly population combined with an unhealthy lifestyle represents a significant risk of increased cancer burden for the people living in Cuba.  In 2012, cancer became a leading cause of death in Cuba, counting for approximately a quarter of all fatal outcomes (3).  Due to these data, Cuba has developed strong mechanisms of cancer prevention, management, and research that are comparable to those in the developed countries.  A comprehensive and systematic approach to cancer prevention, early diagnosis, treatment and palliative care has shown results including increased survival and better quality of life in patients suffering from cancer (4).

Cancer Prevention

The strategy of fighting cancer in Cuba has been established a decade ago.  The main objectives include education and communication of cancer risk factors to the general population, early detection of cancer in the primary healthcare setting, treatment and supportive care in highly specialized institutions, as well as research and development of innovative therapeutic modalities against various types of cancer (5).  A very developed network of primary healthcare institutions enables the physicians to discover cancer in the early stages.  These patients are then referred to specialized institutions where an adequate diagnostics and staging are being made, followed by cancer management techniques.  Following the implementation of the abovementioned strategy, cancer survival rates in Cuba have shown increasing trends, which are comparable to those in developed countries.

Cancer Management

Due to an increased prevalence of cancer, Cuba has invested a significant amount of funds to cancer treatment and research in order to achieve the highest standards in cancer management.  Some of the fascinating achievements of Cuban approach to cancer will be reviewed in this article.

NATIONAL INSTITUTE OF ONCOLOGY AND RADIOBIOLOGY (INOR)

INOR serves as an international medical center that provides advanced and highly sophisticated medical care for cancer patients from all over the globe.  Highest standards in the management of cancer are implemented at this institution with the goal to cure, improve and increase the quality of life of each patient that seeks medical attention.  Advanced treatment modalities, holistic approach to each patient, integrative rehabilitation techniques combined with the use of natural healing methods are just some of the services aimed to increase patient welfare at this institution.  INOR conducts scientific and educational activities related to the nature and biology of cancer.  Various clinical trials are being conducted at this facility in order to investigate and evaluate novel and promising cancer treatment regimens (6).  Patients from more than 50 counties worldwide including Europe, USA and Canada have been treated at this institution with exceptional quality of care.

SUCCESSFUL MANAGEMENT OF LEUKEMIA

In Cuba, the overall survival of kids suffering from acute lymphoblastic leukemia following standard therapeutic protocols is approximately 85% in standard risk patients (7).  The improvement after the application of last generation cytotoxic treatments is seen in approximately 98% of children.  Bone marrow transplants are performed with high success rates.  Additionally, Cuba performed transplantation of cord blood hematopoietic stem cells in order to treat various forms of leukemia.  All of the treatments are totally free of charge for all Cubans.

NON-MELANOMA SKIN CANCER

Skin cancer is among the most frequent cancers in Cuba (8).  The challenges in the treatment of nonmelanoma skin cancers include non-resectable, aggressive and recidivant forms, which are difficult to treat and often lack in proper and effective therapeutic modalities.  The successful management of nonmelanoma skin cancer in Cuba is reflected in the application of the novel combination of two interferons.  More than 400 patients have been treated with this combination with high rates of success, reaching clinical remission in approximately 65% of cases (8).

ORAL CANCER

Oral cancer was among the most frequent forms of cancers in Cuba.  The development of preventative actions including regular oral examination of individuals at least once a year led to significant decrease in the incidence of advanced oral cancer.  The vigilant approach to early detection of oral cancer resulted in significantly higher detection rates of low-grade oral cancers that are more sensitive to treatment and have much better prognosis (9).

Early detection of cancer remains the focus in the fight against malignancy in Cuba.  Highly developed primary health care system represents a pillar stone of Cuban medical care.  The early detection of malignancy on a primary health care level directly resulted in significantly better therapeutic outcomes in patients suffering from various types of cancer.  The increasing aging of Cuban population increased the risks of developing malignancies.  Therefore, Cuba has developed tertiary centersfor cancer diagnostics, staging, treatment and research.  These centers are operating with the highest international standards in cancer management and offer innovative approaches in cancer treatment that are completely free of charge for any Cuban, rating the success of cancer management in Cuba to be among those in highly developed countries.

REFERENCES

  1. Oficina Nacional de Estadistica. Anuario demográfico 2014. http://www.one.cu/anuariodemografico2014.htm. [Online]
  2. National Statistics Bureau (CU). El envejecimiento de la población cubana. http://www.one.cu/publicaciones/cepde/envejecimiento/ envejecimiento2008.pdf. [Online]
  3. Dirección Nacional de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud de Cuba. http://files.sld.cu/dne/files/2015/04/anuario-estadistico-de-salud-2014. [Online] 2018.
  4. WHO. Cuba – Battling cancer with biotechnology. http://www.who.int/features/2013/cuba_biotechnology/en/. [Online] 2018.
  5. Teresa Romero Pérez, Yaima Galán Alvarez and Rolando Camacho Rodríguez. THE BURDEN OF CANCER IN CUBA AND CURRENT STRATEGIES FOR CANCER CONTROL. http://www.cancercontrol.info/cc2016/the-burden-of-cancer-in-cuba-and-current-strategies-for-cancer-control/. [Online] 2018.
  6. INOR. National Institute of Oncology and Radiobiology. http://instituciones.sld.cu/inor/. [Online] 2018.
  7. Results of the treatment of child Acute Lymphoid Leukemia in Cuba. Alejandro, González-Otero et al. s.l. : Revista Cubana de Hematologia, Inmunologia y Hemoterapia, 2014, Vol. 30(1). 36-46.
  8. HeberFERON, formulation based on IFNs alpha2b and gamma for the treatment of non-melanoma skin cancer. Lorenzo, Anasagasti-Angulo et al. 10(6), s.l. : Australasian Medical Journal, 2017.
  9. Research on cancer prevention, detection and management in low- and medium-income countries. R. Sankaranarayanan, P. Boffetta. 10, s.l. : Annals of Oncology, 2010, Vol. 21. 1935–1943.


Canadian Woman’s Successful Use of Cuban Vaccine Gives Mesothelioma Patients Hope

A Cuban vaccine called CIMAvax EGF, which is currently undergoing U.S. testing for its effectiveness in treating mesothelioma and other cancers, has apparently saved the life of a Canadian woman diagnosed with non-small cell lung cancer.  Judy Bryden of Regina, Saskatchewan was originally diagnosed with the terminal form of cancer back in 2016 and given just a year to live. She initially pursued traditional forms of treatment in Canada, including chemotherapy and radiation therapy. After that protocol failed to stop the advancement of her disease she and her husband began researching alternative treatments, and that is when they learned about the success that the Cubans were having with their remarkable cancer vaccine. They contacted an outfit called CubaHeal, which is specifically set up to help people from outside of Cuba to visit the country for treatment, paid a small fee for the process, then traveled there for treatment and to purchase several doses of the vaccine to bring back to her home. The total cost of the trip was $14,500, a fee that was well worth it as her physician says she is now in remission.

CIMAvax has long been discussed as offering great hope for mesothelioma patients. It activates the immune system against a specific protein that has been identified as facilitating cancer cell growth.  It is already in clinical trials in the United States following an agreement between the Roswell Park Comprehensive Cancer Center in New York and the Cuban government that was struck in April of 2015. The Phase I clinical trial began in January of 2017 and is expected to take at least two years, followed by another year or two for the Phase II portion of the trial. The drug has already been approved for use in Bosnia and Herzegovina, Colombia, Cuba, Paraguay and Peru.



A Regina woman wants to spread the word about a vaccine she received in Cuba that she says has kept her alive.

Judy Bryden was diagnosed with lung cancer in 2016, after returning home from a trip with a cold. She underwent numerous scans and, in November 2016, she began chemotherapy. Bryden said the chemotherapy nearly killed her and didn’t cure the cancer. She went through five radiation treatments, and the cancer survived. Following that, a doctor recommended palliative chemotherapy, suggesting Bryden only had one year to live.

“When they told me I had a year to live, I said I was going to prove them wrong. I didn’t know how, but I was going to prove them wrong,” Bryden said.

Bryden refused a second round of chemo. It was at that time that her husband Lorne Bryden first heard about the Cimevax EGF vaccine.

“I searched the internet and found a company called CubaHeal in Brantford, Ontario,” Lorne said. “They were able to put the whole thing together for us, for a fee, of course.”

“When they found (CubaHeal), there was something about it that just felt right. It just felt right at its core,” said Pamela Bryden, Bryden’s daughter.

Lorne submitted Bryden’s medical information, and went on to pay $135. Bryden was approved for treatment, but they had to travel to Cuba.

The vaccine is currently not available in Canada. Health Canada says that is not because of any known safety concerns about the drug. Instead, Health Canada simply does not actively solicit new drug submissions. No application has been submitted for Cimevax EGF yet.

The vaccine works by targeting the epidural growth factor (EGF) which is a protein found naturally in the body. In certain types of cancers, the body produces too much EGF, forcing the cells to grow and divide uncontrollably.

“The company is responsible for submitting an application to Health Canada, so their product can be approved on the Canadian market. Only once we receive that application, will we review an application,” Health Canada spokesperson Renelle Briand said.

The Brydens returned from Cuba in March 2017, with four doses to be injected every 14 days. A CT scan of Bryden this past February found no cancer.

The treatment isn’t cheap. A trip to Havana, plus a year’s supply of injections, costs about $14,500. But it’s still much less than the $65,000 dollar treatment Lorne found for sale in Tijuana, Mexico.

“I wish Cimevax was here for people, because it’s $1,000 a month that we pay,” Bryden said. “It’s worth it.”

Bryden hopes her story encourages others to try the treatment themselves. A recent CT scan shows the cancer has not spread, and CubaHeal has approved another year of vaccines for Bryden. Lorne is planning to leave on March 19 to go pick up the vaccine.



In spite of the U.S. embargo and due to the nature of its economic model being less market oriented than its counterparts and more focused on research for the bettering of the quality of life, Cuba has been able to established a strong and vibrant medical research and biotechnology industry with 1.8 scientists per 1000 inhabitants equal to that in the EU. 

In an attempt to meeting internal demand for controlling and treating chronic diseases the biotechnology industry created the West Havana Scientific Pole in the early 1980s that developed informal and innovative scientific practices that became known for being one of the most advanced globally in establishing and developing a sophisticated and robust indigenous bio-pharmaceutical industry focused on human and veterinary vaccines, bioproducts, medicines, monoclonal antibodies, generics and alternative medicines as well as innovative diagnostic means.

Once described as “Cuba’s billion dollar gamble”, the Havana’s Western Scientific Pole is now includes over 40 scientific institutions and R&D facilities with over 900 international patents for new drugs and treatments and employs more than 30,000 workers. Currently, 11 vaccines and more than 40 therapeutic biological compounds as well as immunodiagnosis are produced in Cuba.  Moreover, at present Cuba has 90 new products being investigated in clinical trials while f 91 products being investigated in more than 60 clinical trials.

It is also one of only four countries to have been accredited by the World Health Organisation for the production of Hepatitis B vaccines.

With research centers such as the The Center for Genetic Engineering and Biotechnology (CIGB), The Center for the Production of Laboratory Animals (CENPALAB)the National Center for Biopreparations (BIOCEN) and the Center of Immunoassay and the Center for Molecular Immunology (CIM) Cuba has become a world leader in many fields of specialist medical research.

The following is a list of some of the most important Cuban medical innovations and medical achievements:

HEBERPROT-P

Developed by the Center for Genetic Engineering and Biotechnology (CIGB) in 2007 Heberprot-P is an innovative Cuban product with EGF as the main ingredient given to patients suffering from non healing and non responding diabetic ulcers. Due to its ability to stimulate cell proliferation and tissue healing Heberprot-P remains to be the only alternative treatment to amputation for diabetic foot ulcers.  About 160,000 diabetic foot ulcer patient have been treated with Heberprot-P with successfully reducing the the risk of amputation by 77%. 

CIMAVAX-EGF

CimaVax-EGF vaccine was devised by researchers from the Center of Immunoassay and the Center for Molecular Immunology (CIM) over a period of 25 years. CimaVax is the first world non small cell lung cancer vaccine that works by by stimulating the immune system to produce antibodies that specifically target and bind with epidermal growth factor (EGF) preventing the cancer from spreading throughout the body.CimaVax-EGF is not a preventive vaccine, rather it acts by restraining the growth and division of cancer cells slowing down initiating an immune response to release antibodies to fight the cause of tumor growth

RACOTUMOMAB

A second non small cell lung cancer developed by enter of Immunoassay and the Center for Molecular Immunology (CIM), Racotumomab (also known as Vaxira) is a therapeutic vaccine that works on a molecule level by inducing a cellular and humoral immune response in tumors tissues by blocking the tumor growth, slowing down it’s development and hence increasing patient’s’ life expectancy and improving quality of life. 

NIMOTUZUMAB

Nimotuzumab (CIMAher), also developed Center of Molecular Immunology, is a humanized anti-EGFR IgG1 therapeutic monoclonal antibody and used for the treatment of squamous cell of head and neck cancers, glioma and nasopharyngeal cancers.  Nimotuzumab is used as either as monotherapy or in combination with radiation and / or chemotherapy. Presently research continues to determine if Nimotuzumab can be used for the treatment of other types of cancers.

HEBERFERON

Developed by the Center for Genetic Engineering and Biotechnology (CIGB), Heberferon   is the first non melanoma skin cancer treatment at the complex and advanced stages.  Heberferon is an immunostimulant in which Interferon alpha 2b and gamma recombinants are combined to stimulates the immune system into a response against tumor inhibiting the growth of the tumour while reducing or eliminating lesions without the need for surgery.

VA-MENGOC-BC

Cuban meningococcal BC vaccine (VA-MENGOC-BC®) was developed by the Finlay Institute in Havana due to a meningococcal outbreak in the 1980s. The first of its type, VA-MENGOC-BC is a bivalent vaccine composed of meningococcal B outer membrane vesicles and meningococcal C capsular polysaccharide.  This vaccine has proven to be very effective with very high safety profile

QUIMI-HIB

Although meningitis and pneumonia have been almost erased in the developed world these diseases remain highly problematic in the developing world due the high cost of the vaccine. Cuban researchers at the University of Havana in conjunction with researchers at the university of Ottawa (Canada) have developed the first synthetically produced antigen. Quimi hib Vaccine works by producing antibodies that resist infection from bacteria  that causes pneumonia and meningitis in  a breakthrough aimed at lowering the cost of immunising children in poorer countries is considered to be safer and purer than vaccines developed from live bacterium or virus. 



heberprot p

A lifetime risk for a diabetic ulcer in patients suffering from Diabetes Type 1 or 2 is approximated to 25%, meaning that every fourth person with diabetes will develop diabetic ulcer (1).  Diabetic foot ulcers represent a medically significant disease complication, with a high incidence of morbidity and mortality in the modern world.  Risks for the development of this serious condition are well established and include the loss of sensation as a consequence of diabetes induced neuropathy, previous occurrences ulcers or amputations, infection, trauma, and the consequences of chronic ischemia due to poor peripheral vascularization (2).  Contemporary treatment options for diabetic foot ulcers are still limited, directly resulting in amputation being the frequent therapeutic solution for the majority of severe ulcers.  Recent advancements in medical science in the treatment of diabetic foot ulcer and its’ complications using Heberprot-P have shown that the use of epidermal growth factor (Heberprot-P) as the treatment of diabetic foot ulcer may lead to the complete wound healing, significantly reducing the risk of amputation.

heberprot p

Most Recent Scientific Data

It is now well recognized that diabetic patients have decreased amounts of epidermal growth factor (EGF) in tissues which directly results in wound healing impairment and subsequently to the increased risk of amputation.  EGF is directly responsible for the growth of epithelial and subepithelial tissues, and promotes reparation processes of tissues that are damaged (3).

Heberprot-P is an innovative recombinant human EGF developed for acceleration of healing process of deep and complex ulcers in both neuropathic and ischemic types of diabetic ulcers.  It currently represents the unique treatment for the most complicated diabetic wounds which are linked with a high risk for amputation.  Efficacy and safety of Heberprot-P have been investigated in numerous clinical trials worldwide, with results demonstrating full wound healing, reduction of ulcer recurrence, as well as a reduction in amputations rates.  Heberprot-P has proven to be a safe and well-tolerated treatment option for the treatment of severe diabetic ulcers, with adverse events mostly consisted of mild and transitory local reactions (4).

Efficacy

A recent extensive meta-analysis involving 2365 participants conducted for the purpose of investigating the effects of growth factors on the healing of diabetic ulcers concluded that growth factors (EGF among them) may lead to complete healing of diabetic foot ulcers (5).  Another meta-analysis and systematic review of literature data conducted on 294 patients also identified favorable patient outcomes following treatment with recombinant human EGF (6).  Efficacy of Hebeprot-P was recently investigated in a clinical study involving patients having extensive, full-thickness lower extremity ulcers.  Administration of Heberprot-P resulted in complete granulation followed by complete wound closure in 94% of patients.  After one year follow-up, only one patient had a relapse of foot ulcer (7).  The interesting mechanistic of healing effects of EGF (Hebeprot-P) has also been investigated recently.  It was recognized that diabetic patients have elevated oxidative stress and low antioxidant reserves.  Application of EGF resulted in significant reduction of oxidative stress and elevation in antioxidant reserves, directly returning balance to oxidative processes in diabetic patients (8).

Safety

The safety profile was recently investigated in the longitudinal, multicenter, post-marketing surveillance study which included 260 patients.  The results were in line with the already known safety profile of Heberprot-P.  Most frequently reported adverse events were mild and reversible in nature, including localized Burning sensation and pain at the injection site, as well as systemic reactions such as chills and shivering (9).  In conclusion, the benefits of Heberprot-P significantly outweigh the risks of this therapy.  Heberprot-P can be safely administered to diabetic patients without the risk of serious and irreversible adverse reactions.

Advancements in Treatment

The recognized therapeutic potential of Heberprot-P prompted another clinical trial that would assess the efficacy and safety of Heberprot-P in patients with high-grade diabetic ulcers.  The study is conducted at the eminent Dasman Diabetes Institute in Kuwait.  Results of numerous studies are promising and justify the further testing of Heberprot-P, a unique and first-in-class therapeutic option for complicated diabetic ulcers.  This provides the opportunity to further evaluate beneficial potentials of Heberprot-P and addresses the unmet medical need of introducing an effective therapeutic modality in the treatment of complex and serious diabetic foot ulcers.

The Unmet Need

An accumulated body of scientific evidence clearly indicates that the use of growth factors (especially recombinant human EGF) is beneficial for complicated diabetic foot ulcers with very high success rates.  Current antimicrobial treatments, as well as the broad spectrum of different procedures involving surgery and drugs, have failed to decrease amputation rates and successfully treat this serious complication of diabetes.  Heberprot-P is a registered treatment for diabetic foot ulcers in dozens of countries worldwide, and it has been successfully used in over 100.000 patients suffering from complex ulcers.  The need for an effective treatment clearly remains, and Heberprot-P has demonstrated to be an effective solution where standard therapeutic options fail.  According to the most current data published by the Center for Disease Control (CDC), more than 100 million Americans have diabetes or prediabetes (10), which represents a high-risk burden for diabetic foot ulcers, considering that every fourth diabetic patient may develop this condition.  Complete regression of the most complicated ischemic diabetic ulcers has been achieved in a significant portion of diabetic patients.  Heberprot-P would address therapeutic needs of patients, in which amputation represents the only treatment option.

BIBLIOGRAPHY

  1. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Boulton AJ, Armstrong DG, Albert SF, Frykberg RG, Hellman R, Kirkman MS, Lavery LA, Lemaster JW, Mills JL Sr, Mueller MJ, Sheehan P, Wukich DK, American Diabetes Association, American Association of Clinical Endocrinologists. s.l. : Diabetes Care, 2008, Vol. 31(8). 1679.
  2. Diabetes in America, 2nd Edition. National, Diabetes Data Group. s.l. : National Institutes of Health, Washington, D.C. 409.
  3. Epidermal growth factor in the treatment of diabetic foot ulcers: an update. Tiaka EK, Papanas N, Manolakis AC, Georgiadis GS.s.l. : Perspect Vasc Surg Endovasc Ther., 2012, Vol. 24(1). 37-44.
  4. Heberprot-P: A Novel Product for Treating Advanced Diabetic Foot Ulcer. Jorge Berlanga DVM MS PhD, José I. Fernández MD, Ernesto López MS, Pedro A. López MD PhD, Amaurys del Río MD, Carmen Valenzuela MS, Julio Baldomero MD, Verena Muzio MD PhD, Manuel Raíces PhD, Ricardo Silva PhD, Boris E. Acevedo MD PhD, Luis Herrera MD PhD. s.l. : MEDICC Rev, 2013, Vol. 15(1). 11.
  5. Growth factors for treating diabetic foot ulcers. Martí-Carvajal AJ, Gluud C, Nicola S, Simancas-Racines D, Reveiz L, Oliva P, Cedeño-Taborda J. s.l. : Cochrane Database Syst Rev, 2015, Vol. (10). CD008548.
  6. Efficacy of Topical Recombinant Human Epidermal Growth Factor for Treatment of Diabetic Foot Ulcer: A Systematic Review and Meta-Analysis. Yang S, Geng Z, Ma K, Sun X, Fu X. s.l. : Int J Low Extrem Wounds, 2016, Vol. 15(2). 120-5.
  7. Efficacy of intralesional recombinant human epidermal growth factor in chronic diabetic foot ulcers. Dumantepe M, Fazliogullari O, Seren M, Uyar I, Basar F. s.l. : Growth Factors, 2015, Vol. 33(2). 128-32.
  8. Healing enhancement of diabetic wounds by locally infiltrated epidermal growth factor is associated with systemic oxidative stress reduction. Ojalvo AG, Acosta JB, Marí YM, Mayola MF, Pérez CV, Gutiérrez WS, Marichal II, Seijas EÁ, Kautzman AM, Pacheco AE, Armstrong DG. s.l. : Int Wound J, 2017, Vol. 14(1). 214-225.
  9. Characterization of adverse events during the treatment with heberprot-p® in four Cuban provinces. Alina Ramona Alvarez Crespo, Liuba Alonso Carbonell, Isis Belkis Yara Alos, Ana Julia Garcia Milian, María Acelia Marrero Miragaya. s.l. : Horizonte Sanitario, 2017, Vol. 17.
  10. National Center for Chronic Disease Prevention and Health Promotion. National Diabetes Statistics Report, 2017. s.l. : Center for Disease Control, 2017.


The Cuban biotechnology industry is known worldwide. The human and veterinary vaccines, bioproducts, drugs, diagnostic means and monoclonal antibodies created by brilliant scientists, in top-level facilities, place Cuba as one of the developing nations, together with India and Brazil, with more advances in this sector.

The BioCubaFarma Business Group, one of the most economically powerful in the country, is responsible for leading the biotechnology and pharmaceutical industries. This organization has registered products and exports to more than 50 countries, has 1,800 patents abroad and its annual income exceeds 2,000 million dollars. Among the institutions attached to the huge Group, which employs more than 22,000 workers, are the Center for Genetic Engineering and Biotechnology (CIGB), the Center for the Production of Laboratory Animals (CENPALAB), the National Center for Biopreparations (BIOCEN), the Center of Immunoassay and the Center for Molecular Immunology (CIM).

What are the medications, made in Cuba, with the most international prestige? PanamericanWorld proposes to approach five creations, unique in the world, born of the brilliance and long years of research by Cuban scientists.

HEBERPROT-P: THE BEST TREATMENT FOR DIABETIC FOOT ULCERS

According to the World Health Organization, some 300 million people suffer from diabetes, and of these, between 15% and 35% may suffer amputation of one of their extremities. The Cuban drug Heberprot-P, the only one of its kind in the world, has been able to reduce amputations by diabetic foot ulcer in Cuban patients more than four times. Born from the creative genius of a team of scientists, led by Dr. Jorge Berlanga, at the CIGB, the drug is used in more than 20 countries.The treatment includes injection into the affected area of he person and accelerates the healing process of the skin, so that the wound would be closed in a period of approximately three months.

VACCINE CIMAVAX-EGF: A HOPE AGAINST LUNG CANCER

The chances of survival for people diagnosed with lung cancer at an advanced stage are very low; However, with CIMAvax-EGF a new hope has appeared. This vaccine was created by researchers from the CIM who took 25 years to develop the product. The treatment slows down the growth of cancer cells and, therefore, prevents the disease from spreading throughout the body and thereby prolongs people’s lives. The scientists clarify that it is not a preventive vaccine, but therapeutic, although it has also been used in those with higher risks of suffering from the disease.

The CIM also developed the VAXIRA vaccine (known as Racotumomab) that works on a molecule found in all cancer cells. Scientists hope that, in the future, the drug may be effective against leukemia and other tumors that accompany lung, colon, prostate and breast cancers.

CIMAvax-EGF caught the attention of scientists from the Roswell Park Cancer Institute in New York who continue to evaluate the possibility of taking this medication to the United States, which would be a milestone, because the Washington Blockade has prevented access to Cuban inventions.

Policosanol (PPG): A Natural Product to Lower Cholesterol

This drug, made from the wax of sugar cane, is used mainly to lower cholesterol, although the product also has other applications, since its antiplatelet, anti-ischemic and antithrombotic effects have been demonstrated; In addition, some take the medication because they consider that it invigorates the male genital tract. The PPG, being natural, has few contraindications, unlike what happens with other drugs on the international market for cholesterol.

Venezuela is one of the biggest consumers of PPG and Cuba also markets it in Serbia, Slovakia and Spain, among other nations.

Va-Mengoc-BC: Very Effective Vaccine Against Meningococci B and C

During the 80s of the last century, Cuba suffered an outbreak of meningococcal disease. The scientists worked intensely to find a solution and the Finlay Institute of Havana created VA-MENGOC-BC, a bivalent vaccine composed of meningococcal B outer membrane vesicles and meningococcal C capsular polysaccharide. It is currently the only commercially available drug in the world that attacks meningococci B and C.

In Cuba, more than 60 million doses of the vaccine have already been applied. The drug has proven to be very effective and with a high safety profile, as recognized by the World Health Organization.

Neuroepo: A Medication to Slow the Progression of Alzheimer’s

Population aging is one of the biggest problems facing Cuba. Currently, Alzheimer’s is the sixth cause of death in the country, among people over 60 years of age and, by 2040, this disease could affect 2.7% of Cubans. Today, more than 35 million people in the world have Alzheimer’s and there is no medication that is able to cure or stop its progression. In this context, the CIM scientists created a drug, called NeuroEpo, that delays the expansion of this disease.

“It would be the first time it is used on people and we have to wait for the results. This compound does not prevent Alzheimer’s disease, nor does it eliminate it, but the preclinical results are encouraging in that it could help to change the course of the disease, that is, slow down the deterioration that the patient inevitably suffers. Alzheimer’s is a neurodegenerative disease without regression, she will move forward. What we want is to help delay this degenerative process and improve the quality of life of that person, and of the family, “acknowledged CIM researcher Leslie Pérez Ruiz.

Upcoming Creations

Cuban scientists are working on a clinical trial with Heberferon, which acts on renal carcinoma and in patients with malignant brain tumors;



A new approach to medical education in Cuba is developing. The approach encompasses sweeping new and advanced methods while deepening effective educational methods. The objective of these changes is to achieve the following:

  • Enhance the practical training and knowledge base in order to address the need of a diverse population by producing a generation competent doctors with a deep knowledge base and scope of obligations and responsibilities
  • Produce, via extensive training an army of scientifically oriented and socially committed students

These two principals were the cornerstone in guiding the establishment of successful and innovative Cuban medical education system, at the Faculty of Medicine at the University of Havana was the first to adopt said reforms back in the 1960. In spite of the resistance to a universal public healthcare and national primary healthcare to the populous. Such reforms were a major positive contributor to extending medical services to the deprived rural areas of the island and addressed the urgent need of establishing a training program for hundreds of doctors and physicians prepared and committed to this new vision.

As an initial commitment, and in 1959, students in their final year of medical training program held a series of heated meetings in order to vote on these new moral principles. The end result was an overwhelming vote in support of a decision to send hundreds of volunteers to where they were most needed, hence the establishment of the “Cuban camp”.

The principled students at the University of Havana elevated their initiative to the Ministry of Public Health, which swiftly agreed to establish 318 new jobs to serve the mountains areas. This was the origin of the “Rural Medical Services” program which attributed to the involvement of hundreds of new graduates over the next decade and lay the groundwork for the laws that would establish community service as a requirement.

Historical milestones of the Republic of Cuba’s Medical Education

  • 1726: The first medical program was established in Cuba
  • 1728: The establishment of the University of Havana, including Faculty of Medicine
  • 1842: The University of Havana adopts a reformed medical curriculum with focus on scientific principles that involved the introduction of clinical medicine
  • 1919: The establishment of a six-year Flexnerian modeled program to govern the basic, preclinical and clinical sciences
  • 1942: The improvement of the Flexnerian modeled program to govern the individual patient care, which included a teaching hospital for students, interns and residents
  • 1956: The University of Havana was shut down as per General Batista’s orders
  • 1959: The Faculty of Medicine of the University is re-established with 23 professors
  • 1963: An Emergency program was introduced to address the urgent need of training medical teams to handle the shortfall in public health care
  • 1970: The creation of primary model and primary care; community-based integrated polyclinics programs
  • 1976: The supervision of medical education became one of the Republic of Cuba’s Ministry of Public Health duties.
  • 1976: The Higher Institutes of Medical Sciences in Havana, Santa Clara and Santiago de Cuba was established
  • 1980: The establishment of 54 medical schools offering various medical specializations and covered all Cuban provinces
  • 1982: The strengthening of the selection criteria of medical students include vocational, motivational, as well as academic performance.
  • 1982 – 1985: Curricular reform for obtaining the Basic General Practitioner (BGP) for the family doctor program which offers more training in community based settings that emphasis on the medical school campus and hospital servicing
  • 1984: The family physician program was introduced
  • 1984: The creation of a comprehensive General/ Family Medicine program as a new medical specialty
  • 1986: The application of the first national practical and theoretical licensing examinations are applied with the utilization of external inspectors
  • 1996: The strengthening of the “Pillars of quality” assurance for medical education program, which resulted in stronger requirements for accreditation of established medical universities and centers.
  • 1996: The enforcement of the medical education credit system
  • 1997: The establishment of Master in Medical Education program
  • 1999: The establishment of the Latino Medical School (ELAM)



In short words


CubaHeal Medical is a global organization specialized in facilitating medical treatments, medical education, in addition to patient and student care in the Republic of Cuba. CubaHeal is a loyal supporter of the Republic of Cuba, the Cuban people, the Cuban revolution, and the Cuban revolutionary leadership.




Subscribe


Sign up for CUBAHEAL newsletter to receive all the news offers and discounts.



CUBAHEAL | All rights reserved | Developed and designed by Moustaide CO